These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35994504)

  • 1. The Influence of Sex, Body Mass Index, and Age on Cellular and Humoral Immune Responses Against Measles After a Third Dose of Measles-Mumps-Rubella Vaccine.
    Quach HQ; Chen J; Monroe JM; Ratishvili T; Warner ND; Grill DE; Haralambieva IH; Ovsyannikova IG; Poland GA; Kennedy RB
    J Infect Dis; 2022 Dec; 227(1):141-150. PubMed ID: 35994504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.
    Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Kulkarni A; Audet S; Mercader S; McGrew M; Hickman CJ; Bellini WJ; Shivakoti R; Griffin DE; Beeler J
    J Infect Dis; 2016 Apr; 213(7):1115-23. PubMed ID: 26597262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.
    Haralambieva IH; Ovsyannikova IG; Kennedy RB; Goergen KM; Grill DE; Chen MH; Hao L; Icenogle J; Poland GA
    Vaccine; 2020 Jan; 38(5):1249-1257. PubMed ID: 31732325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Events Among Young Adults Following a Third Dose of Measles-Mumps-Rubella Vaccine.
    Marin M; Fiebelkorn AP; Bi D; Coleman LA; Routh J; Curns AT; McLean HQ
    Clin Infect Dis; 2021 Oct; 73(7):e1546-e1553. PubMed ID: 32766827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between markers of cellular and humoral immunity to rubella virus following a third dose of measles-mumps-rubella vaccine.
    Crooke SN; Ovsyannikova IG; Kennedy RB; Warner ND; Poland GA
    Vaccine; 2020 Nov; 38(50):7897-7904. PubMed ID: 33158591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibody titers against D8 genotype and persistence of measles humoral and cell-mediated immunity eight years after the first dose of measles, mumps, and rubella vaccine in Brazilian children.
    Kegele Lignani L; de Vasconcellos Carvalhaes de Oliveira R; Matos Dos Santos E; Antonio Bastos Camacho L; Reis Xavier J; Regina da Silva E Sá G; Mendonça Siqueira M; Marques Vieira da Silva A; Gil Melgaço J; Dos Santos Alves N; de Lourdes de Sousa Maia M; Caetano Prates Melo E
    Vaccine; 2024 Mar; 42(8):2065-2071. PubMed ID: 38413280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults.
    Kaaijk P; Wijmenga-Monsuur AJ; Ten Hulscher HI; Kerkhof J; Smits G; Nicolaie MA; van Houten MA; van Binnendijk RS
    Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood.
    Rasheed MAU; Hickman CJ; McGrew M; Sowers SB; Mercader S; Hopkins A; Grimes V; Yu T; Wrammert J; Mulligan MJ; Bellini WJ; Rota PA; Orenstein WA; Ahmed R; Edupuganti S
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19071-19076. PubMed ID: 31481612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mumps Virus Nucleoprotein and Hemagglutinin-Specific Antibody Response Following a Third Dose of Measles Mumps Rubella Vaccine.
    Latner DR; Parker Fiebelkorn A; McGrew M; Williams NJ; Coleman LA; McLean HQ; Rubin S; Hickman CJ
    Open Forum Infect Dis; 2017; 4(4):ofx263. PubMed ID: 29308410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
    Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine.
    Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Zhang C; Ngo L; Rubin S
    Open Forum Infect Dis; 2014 Dec; 1(3):ofu094. PubMed ID: 25734162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population.
    Date AA; Kyaw MH; Rue AM; Klahn J; Obrecht L; Krohn T; Rowland J; Rubin S; Safranek TJ; Bellini WJ; Dayan GH
    J Infect Dis; 2008 Jun; 197(12):1662-8. PubMed ID: 18419346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
    St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose.
    Kaaijk P; Nicolaie MA; van Rooijen D; van Houten MA; van der Klis FR; Buisman AM; van Binnendijk RS
    Open Forum Infect Dis; 2020 Nov; 7(11):ofaa505. PubMed ID: 33269296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.
    Wanlapakorn N; Puenpa J; Thongmee T; Srimuan D; Thatsanathorn T; Vongpunsawad S; Poovorawan Y
    Vaccine; 2020 May; 38(24):4016-4023. PubMed ID: 32331806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
    J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.